Abstract
We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.
Original language | English |
---|---|
Pages (from-to) | 1837-1841 |
Number of pages | 5 |
Journal | Leukemia Research |
Volume | 32 |
Issue number | 12 |
DOIs | |
Publication status | Published - 01-12-2008 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
- Cancer Research